Elsevier

Annals of Oncology

Volume 27, Supplement 6, 1 October 2016, Page vi452
Annals of Oncology

Submitted abstracts
NSCLC, metastatic
1296TiP - A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)

https://doi.org/10.1093/annonc/mdw383.96Get rights and content
Under an Elsevier user license
open archive

Cited by (0)